CSF3 and COVID-19: Similarly, the therapeutic potential behind antagonizing G-CSF has not been addressed, but recent observations of detrimental consequences of the opposite approach (G-CSF administration) in COVID-19 patients are proof of the concept (Taha and others 2020; Sereno and others 2021).